-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle[1,2]. Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor, and does not bind appreciably to any of the other murine EP receptors or DP, TP, FP, or IP receptors[3]. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells[4].
[1]. Regan J W, Bailey T J, Pepperl D J, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol, 1994, 46(2): 213-220.
[2]. Talpain E, Armstrong R A, Coleman R A, et al. Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. British Journal of Pharmacology, 1995, 114(7): 1459-1465.
[3]. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol, 1997, 122(2): 217-224.
[4]. Lawrence, R.A., and Jones, R.L. Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. British Journal of Pharmacology, 1992, 105(4): 817-824.
-
- Properties
-
Overview